SEC Comment Letter for NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379) (NWBO) — Dec 31, 2014
NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379)
Date: Dec. 31, 2014 · CIK: 0001072379 · Accession: 0000000000-14-067508
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-35737
Letter
December 31 , 2014 Via E -mail Linda F. Powers Chief Executive Officer Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814
Re: Northwest Biotherapeutics, Inc. Form 10-K for Fiscal Year Ended December 31 , 2013 Filed April 1, 2014 File No. 001-35737
Dear Ms. Powers :
We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
December 31 , 2014 Via E -mail Linda F. Powers Chief Executive Officer Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 Re: Northwest Biotherapeutics, Inc. Form 10-K for Fiscal Year Ended December 31 , 2013 Filed April 1, 2014 File No. 001-35737 Dear Ms. Powers : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Riedler Assistant Director